Media coverage about Intersect ENT (NASDAQ:XENT) has been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intersect ENT earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 44.7548012666487 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have impacted Accern’s rankings:
Several brokerages have commented on XENT. Bank of America Corporation boosted their target price on Intersect ENT from $33.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, September 11th. Canaccord Genuity increased their target price on shares of Intersect ENT from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Wednesday, September 13th. Zacks Investment Research upgraded Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a report on Thursday, October 5th. Piper Jaffray Companies restated a “buy” rating and set a $35.00 price target on shares of Intersect ENT in a report on Tuesday, August 22nd. Finally, BidaskClub cut Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $27.70.
Shares of Intersect ENT (XENT) traded up 1.53% on Friday, reaching $29.80. The company’s stock had a trading volume of 25,218 shares. The company’s 50-day moving average is $29.95 and its 200 day moving average is $26.91. Intersect ENT has a 12-month low of $7.65 and a 12-month high of $33.25. The company’s market capitalization is $869.83 million.
Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.11. The business had revenue of $24.00 million during the quarter, compared to analysts’ expectations of $22.62 million. Intersect ENT had a negative return on equity of 17.60% and a negative net margin of 22.94%. The business’s quarterly revenue was up 24.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.21) earnings per share. Equities analysts anticipate that Intersect ENT will post ($0.61) earnings per share for the current fiscal year.
In related news, insider Lisa D. Earnhardt sold 20,000 shares of the stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $28.37, for a total transaction of $567,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jeryl L. Hilleman sold 12,833 shares of the stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $29.00, for a total value of $372,157.00. Following the transaction, the chief financial officer now directly owns 27,833 shares of the company’s stock, valued at $807,157. The disclosure for this sale can be found here. Insiders have sold 134,563 shares of company stock valued at $4,014,904 in the last quarter. 13.70% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/27/intersect-ent-xent-earns-daily-news-impact-rating-of-0-18.html.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.